Status:
UNKNOWN
Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Hyperkalemia
Chronic Renal Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failur...
Eligibility Criteria
Inclusion
- patients regularly attending the nephrological clinic or the dialysis unit
- persistent potassium concentration above 5 mEq/L
Exclusion
- Patients suffering from active ischemic heart disease
- Patient with a recent history of arrhythmia
- Patients treated regularly with ß blockers
- Patients treated regularly with salbutamol or other ß2AR agonists
- Patients suffering from persistent tachycardia (pulse \> 100 beats/min)
- Patients who are hemodynamically unstable
- Patients suffering from any acute illness
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00162487
Start Date
August 1 2002
Last Update
October 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120